Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Sep;4(3):275-80.
doi: 10.1159/000346284. Epub 2012 Dec 20.

Treatment of severe cold contact urticaria with omalizumab: case reports

Petra Brodská  1 , Peter Schmid-Grendelmeier
Affiliations
Case Reports

Treatment of severe cold contact urticaria with omalizumab: case reports

Petra Brodská et al. Case Rep Dermatol. 2012 Sep.

Abstract

We report 2 patients with cold urticaria with different response to treatment with omalizumab (Xolair(®)). Cold contact urticaria (CCU) is a common subtype of physical urticaria. It is characterized by the development of wheal and/or angioedema within minutes after cold contact. Clinical manifestation of CCU can range from mild, localized whealing to life-threatening anaphylactic shock reactions. Omalizumab has been described to be useful in cases of chronic urticaria and may be an interesting option for treatment of CCU. We describe one patient with significant and long-lasting improvement of symptoms and one without any improvement after anti-immunoglobulin E therapy. In our case reports, we want to highlight that there is still a small group of patients without benefit from omalizumab treatment. It is necessary to identify this minor subgroup of patients where omalizumab does not represent an effective treatment possibility.

Keywords: Anti-immunoglobulin E; Cold contact urticaria; Omalizumab; Physical urticaria.

PubMed Disclaimer

References

    1. Buss YL, Sticherling M. Cold urticaria; disease course and outcome – an investigation of 85 patients before and after therapy. Br J Dermatol. 2005;153:440–441. - PubMed
    1. Siebenhaar F, Weller K, Mlynek A, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol. 2007;32:241–245. - PubMed
    1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter CG, Church MK, Gimenez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427–1443. - PubMed
    1. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415–1418. - PubMed
    1. Xolair: summary of product characteristics. European Medicines Agency; 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info....

Publication types